BAO PHARMA-B Shares Surge Over 8% in Late Trading as SJ02 Commercialization Begins and KJ103 NDA Submission Expected

Stock News04-01

BAO PHARMA-B (02659) saw its shares rise more than 8% in late trading. At the time of writing, the stock was up 6.57%, trading at HK$97.3, with a turnover of HK$84.53 million. The movement follows the company's recent release of its full-year results. During the reporting period, the company achieved total revenue of RMB 49 million and continued to invest in research and development to build the core competitiveness of its products. The company's three core products (KJ017, KJ103, and SJ02) have each achieved rapid progress in registration, clinical trials, and commercialization. Notably, SJ02 completed its first batch order delivery in November 2025, marking the full commencement of its commercialization process. It is also noteworthy that another core product, KJ103 (a recombinant IgG-degrading enzyme), has demonstrated the company's capability in addressing urgent clinical needs. Targeting the medical challenge of desensitization before kidney transplantation, the company initiated a Phase III trial in August 2025, which was completed in March 2026. Submission of a New Drug Application (NDA) to regulatory authorities is expected in the first half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167543547?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167543547","market":"nz","top_or_hot":-1,"title":"BAO PHARMA-B Shares Surge Over 8% in Late Trading as SJ02 Commercialization Begins and KJ103 NDA Submission Expected","media":"Stock News","content":"<p>BAO PHARMA-B (02659) saw its shares rise more than 8% in late trading. At the time of writing, the stock was up 6.57%, trading at HK$97.3, with a turnover of HK$84.53 million. The movement follows the company's recent release of its full-year results. During the reporting period, the company achieved total revenue of RMB 49 million and continued to invest in research and development to build the core competitiveness of its products. The company's three core products (KJ017, KJ103, and SJ02) have each achieved rapid progress in registration, clinical trials, and commercialization. Notably, SJ02 completed its first batch order delivery in November 2025, marking the full commencement of its commercialization process. It is also noteworthy that another core product, KJ103 (a recombinant IgG-degrading enzyme), has demonstrated the company's capability in addressing urgent clinical needs. Targeting the medical challenge of desensitization before kidney transplantation, the company initiated a Phase III trial in August 2025, which was completed in March 2026. Submission of a New Drug Application (NDA) to regulatory authorities is expected in the first half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BAO PHARMA-B Shares Surge Over 8% in Late Trading as SJ02 Commercialization Begins and KJ103 NDA Submission Expected</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBAO PHARMA-B Shares Surge Over 8% in Late Trading as SJ02 Commercialization Begins and KJ103 NDA Submission Expected\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-01 16:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BAO PHARMA-B (02659) saw its shares rise more than 8% in late trading. At the time of writing, the stock was up 6.57%, trading at HK$97.3, with a turnover of HK$84.53 million. The movement follows the company's recent release of its full-year results. During the reporting period, the company achieved total revenue of RMB 49 million and continued to invest in research and development to build the core competitiveness of its products. The company's three core products (KJ017, KJ103, and SJ02) have each achieved rapid progress in registration, clinical trials, and commercialization. Notably, SJ02 completed its first batch order delivery in November 2025, marking the full commencement of its commercialization process. It is also noteworthy that another core product, KJ103 (a recombinant IgG-degrading enzyme), has demonstrated the company's capability in addressing urgent clinical needs. Targeting the medical challenge of desensitization before kidney transplantation, the company initiated a Phase III trial in August 2025, which was completed in March 2026. Submission of a New Drug Application (NDA) to regulatory authorities is expected in the first half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1167543547","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167543547","pubTimestamp":1775030424,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BAO PHARMA-B (02659) saw its shares rise more than 8% in late trading. At the time of writing, the stock was up 6.57%, trading at HK$97.3, with a turnover of HK$84.53 million. The movement follows...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard"},"translate_title":"随着SJ02商业化开始和KJ103 NDA提交的预期，宝药业-B股价尾盘飙升逾8%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02659":1},"content_text":"BAO PHARMA-B (02659) saw its shares rise more than 8% in late trading. At the time of writing, the stock was up 6.57%, trading at HK$97.3, with a turnover of HK$84.53 million. The movement follows the company's recent release of its full-year results. During the reporting period, the company achieved total revenue of RMB 49 million and continued to invest in research and development to build the core competitiveness of its products. The company's three core products (KJ017, KJ103, and SJ02) have each achieved rapid progress in registration, clinical trials, and commercialization. Notably, SJ02 completed its first batch order delivery in November 2025, marking the full commencement of its commercialization process. It is also noteworthy that another core product, KJ103 (a recombinant IgG-degrading enzyme), has demonstrated the company's capability in addressing urgent clinical needs. Targeting the medical challenge of desensitization before kidney transplantation, the company initiated a Phase III trial in August 2025, which was completed in March 2026. Submission of a New Drug Application (NDA) to regulatory authorities is expected in the first half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167543547","isCrawlerRequest":true}